---
id: "entity-boston-consulting-group-d1"
type: "entity"
entityType: "organization"
canonicalName: "Boston Consulting Group"
aliases: ["BCG"]
source_url: "https://hbr.org/2024/12/how-to-create-value-systematically-with-gen-ai"
source_title: "How to Create Value Systematically with Gen AI"
source_timestamps: ["§ Visionary Innovation"]
tags: ["consulting", "research"]
related: ["claim-ai-doubles-drug-discovery-productivity"]
sources: ["spine"]
sourceVaultSlug: "hbr-seg-spine"
originDay: 1
articleStem: "hbr-nm-98-create-value-systematically-genai"
sourceUrl: "https://hbr.org/2024/12/how-to-create-value-systematically-with-gen-ai"
sourceTitle: "How to Create Value Systematically with Gen AI"
---
# Boston Consulting Group (BCG)

**Profile.** Boston Consulting Group (BCG) is a global consulting firm whose recent study is cited to demonstrate AI's impact on **Visionary Innovation** (Level 4). The study suggests AI may be **doubling productivity in drug discovery** by increasing the rate of molecules successfully advancing through clinical trials from **5–10% to 9–18%** — the basis of [[claim-ai-doubles-drug-discovery-productivity]].

**Role in the source.** Evidentiary anchor for the top of the pyramid; the authors substituted this BCG citation for previously used, later-withdrawn MIT research in June 2025.

**Enrichment.** BCG publishes research on AI in pharma/drug discovery, often citing case-based evidence of improved hit rates and pipeline success. Independent caution: such figures are indication-specific and small-N; "doubling" is best read as a doubling of success probability at particular stages, not an industry-wide average. Note BCG also appears in the enrichment as the site of a controlled experiment where consultants using GPT-4 completed creative tasks ~25% faster — relevant to [[claim-individual-gains-insufficient]]. Canonical reference: BCG global consulting firm home page.